Metagenomi Therapeutics (MGX) Gains from Sales and Divestitures (2024 - 2026)
Metagenomi Therapeutics (MGX) reported Gains from Sales and Divestitures of $23357.0 for Q1 2026, up 105.41% year-over-year from $11371.0 in Q1 2025, and down 92.42% quarter-over-quarter from $308058.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 3 years of Gains from Sales and Divestitures data on file, last reported at $23357.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $23357.0, up 105.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $23357.0 (up 105.41% YoY), and the FY2025 annual result was $308058.0, down 38.28% from the prior year.
- Gains from Sales and Divestitures slipped to $23357.0 in Q1 2026 per MGX's latest filing, from $308058.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $499148.0 in Q4 2024 and troughed at $11371.0 in Q1 2025.
- A 3-year average of $174412.8 and a median of $114283.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
- On a YoY basis, Gains from Sales and Divestitures climbed as much as 1129.21% in 2025 and fell as far as 90.05% in 2025.
- A 3-year view of Gains from Sales and Divestitures shows it stood at $499148.0 in 2024, then slumped by 38.28% to $308058.0 in 2025, then slumped by 92.42% to $23357.0 in 2026.
- Business Quant data shows MGX's Gains from Sales and Divestitures at $23357.0 in Q1 2026, $308058.0 in Q4 2025, and $250280.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,357.00 |
| Mar 31, 2026 | 23,357.00 |
| Dec 31, 2025 | 308,058.00 |
| Dec 31, 2025 | 308,058.00 |
| Sep 30, 2025 | 250,280.00 |
| Sep 30, 2025 | 250,280.00 |
| Jun 30, 2025 | 88,299.00 |
| Jun 30, 2025 | 88,299.00 |
| Mar 31, 2025 | 11,371.00 |
| Mar 31, 2025 | 11,371.00 |
| Dec 31, 2024 | 499,148.00 |
| Dec 31, 2024 | 499,148.00 |
| Sep 30, 2024 | 20,361.00 |
| Sep 30, 2024 | 20,361.00 |
| Jun 30, 2024 | 254,558.00 |
| Jun 30, 2024 | 254,558.00 |
| Mar 31, 2024 | 114,283.00 |
| Mar 31, 2024 | 114,283.00 |